Norway· NO-ID_6B89B7AB-BAB2-4850-81AB-7C95AC49B6CF
Flixabi
A infliximab product containing infliximab, registered in Norway by Samsung Bioepis NL B.V.. The same ATC class is registered in 14 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Infliximab is registered in 14 of 19 countries.
Countries holding a registration under ATC L04AB02 (infliximab), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 9 of them publish a price we can compare per daily dose
Infliximab · ATC L04AB02
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of infliximab costs, country by country.
Normalised to the WHO defined daily dose (3.75 mg), the median price runs from $0.31 in Finland to $24.45 in Switzerland — a ×79 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Infliximab · price per daily dose (3.75 mg)
USD · FX 28 Sept 2026
- CH Switzerland$24.45
- FI Finland$0.31
The record
At a glance
FEST (Norway)- Active substance
- Infliximab
- Manufacturer
- Samsung Bioepis NL B.V.
- Country
- Norway (NO)
- ATC code
- L04AB02
- ATC class
- Infliximab
- Defined daily dose
- 3.75 mg, P
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 5
2 priced- no_varenummer5635073 x 100NOK 8225.4
- no_varenummer148231100NOK 2766
- gtin8809593170495
- no_merkevare_idID_6B89B7AB-BAB2-4850-81AB-7C95AC49B6CF
- gtin8809593171270
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
443 interactions on record for infliximab.
Graded by severity as the source publishes them — 290 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Infliximab · interactions on record
443 records
- 290 severe
- 146 moderate
- 7 minor
Most severe, free to view
- PrednisoloneA07EA01severe
- HydrocortisoneA07EA02severe
- PrednisoneA07EA03severe
- BetamethasoneA07EA04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Infliximab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaFLIXABISamsung Bioepis NL B.V., Delft
- FinlandFlixabiSAMSUNG BIOEPIS NL B.V.
- SpainFLIXABI 100MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONSamsung Bioepis Nl B.V.
- United KingdomFlixabi 100mg powder for concentrate for solution for infusion vialsBiogen Idec Ltd
- BelgiumFlixabi 100 mgSamsung Bioepis NL
- SwitzerlandFlixabi 100 mg, Pulver für ein Konzentrat zur Herstellung einer InfusionslösungSamsung Bioepis CH GmbH
- IrelandFlixabi 100 mg powder for concentrate for solution for infusionSamsung Bioepis NL B.V.
- IcelandFlixabiSamsung Bioepis NL B.V.
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Remicade, Remsima
- Liechtenstein · Remicade, Remsima
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d1f99599-ec0d-4be6-96de-4e7b2ee1b2b5 GET /v1/drugs/d1f99599-ec0d-4be6-96de-4e7b2ee1b2b5?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Pulver til konsentrat til infusjonsvæske, oppløsning",
"source": "fest",
"status": "A",
"atc_name": "Infliksimab",
"merkevare_id": "ID_6B89B7AB-BAB2-4850-81AB-7C95AC49B6CF",
"name_form_strength": "Flixabi pulv til kons til inf væske, oppl 100 mg",
"prescription_group": "C"
}See everything about infliximab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.